The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study

Carmine M. Carapella, Marco G. Paggi, Fabio Cattani, Giovanni B. Ciottoli, Aristide Floridi, Bruno Iandolo, Laura Raus, Antonio Riccio, Antonio Caputo

Research output: Contribution to journalArticlepeer-review


Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalJournal of Neuro-Oncology
Issue number1
Publication statusPublished - May 1989


  • brain tumor metabolism
  • Lonidamine
  • malignant glioma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'The potential role of lonidamine (LND) in the treatment of malignant glioma - Phase II study'. Together they form a unique fingerprint.

Cite this